ITLN1 and metabolic syndrome: Plasma omentin levels and omentin mRNA expression in visceral adipose tissue are reduced in obese individuals(20) and omentin levels may serve as predictors of metabolic outcomes or comorbidities related to obesity.(21) Since obesity is common in PCOS, alterations in adipokine levels and increased prevalence of metabolic syndrome are expected in PCOS patients.(13) However, the complex pathogenesis of PCOS limits the use of markers related to fat metabolism and inflammation in diagnostic criteria, as a single serum marker may have low sensitivity and specificity in predicting PCOS.